Navigation Links
Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease
Date:2/2/2009

ROCHESTER, Minn., Feb. 2 /PRNewswire-USNewswire/ -- Men who experience erectile dysfunction between the ages of 40 and 49 are twice as likely to develop heart disease than men without dysfunction, according to a new Mayo Clinic study.

Researchers also found that men with erectile dysfunction have an 80 percent higher risk of heart disease.

"The highest risk for coronary heart disease was in younger men," says researcher Jennifer St. Sauver, Ph.D. The study was published in the February 2009 issue of Mayo Clinic Proceedings. The results suggest that younger men and their doctors may need to consider erectile dysfunction a harbinger of future risk of coronary heart disease -- and take appropriate steps to prevent it, says Dr. St. Sauver.

"The importance of the study cannot be overstated," writes Martin Miner, M.D., in an editorial in the same issue of Mayo Clinic Proceedings. The results "raise the possibility of a 'window of curability,' in which progression of cardiac disease might be slowed or halted by medical intervention," writes Dr. Miner, who practices at the Men's Health Center, Miriam Hospital, Providence, R.I.

Erectile dysfunction is common, and prevalence increases with age. It affects 5 to 10 percent of men at age 40. By age 70, from 40 to 60 percent of men have the condition.

Dr. St. Sauver says researchers wanted to learn more about the connections between age, cardiovascular disease and erectile dysfunction. Two previous studies, both published in 2005, laid groundwork for the Mayo Clinic study. One found that erectile dysfunction predicted an increased risk of heart disease, but the erectile dysfunction of the study participants was not assessed with an externally validated questionnaire and cardiac events were not subjected to standardized review for diagnostic accuracy [Thompson et al, JAMA, 2005]. The second predicted that future cardiovascular disease
'/>"/>

SOURCE Mayo Clinic
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VIDEO from Medialink and International HIFU: New Prostate Cancer Procedure Being Tested in US Clinical Trials
2. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
3. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
4. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
5. Patient Enrollment in Urgent(R) PC SUmiT Clinical Trial Completed Ahead of Schedule
6. Clinical Update - Debio 025 in Hepatitis C
7. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
8. Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis
9. Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
10. Novel Product for Post Surgical Scar Formation Entering Clinical Development
11. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ... board of directors of Advaxis, Inc. ("Advaxis" or the ... board has breached its fiduciary duties to shareholders. ... on an investing website reporting that Advaxis had misrepresented ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has repositioned ... market share and grab a foothold in the hydroponic, hemp ... capabilities and a presence in the sector, and recently partnering ... growth of hemp and medical marijuana, iMD is committing to ...
(Date:1/23/2015)... MONMOUTH JUNCTION, N.J. , Jan. 23, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... surgery patients, announced the receipt of $385,642, net ... approved participant of the Technology Business Tax Certificate ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... Calif., Dec. 9 Portola,Pharmaceuticals, a biopharmaceutical company ... disease, inflammatory disease,and cancer, today announced that it ... II clinical trial of PRT060128, the Company,s,novel P2Y12 ... intervention (PCI). , ...
... FRANCISCO, Dec. 8 Millennium: The Takeda Oncology ... follow up of patients from the large, international ... for patients with previously untreated multiple myeloma given ... demonstrated consistent efficacy in all patient sub-groups, including ...
Cached Medicine Technology:Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention 2Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6
(Date:1/22/2015)... Hawley, PA (PRWEB) January 22, 2015 Woodloch ... Pocono Mountains, has been selected by TripAdvisor as the number ... and the 6th best in the world for their annual ... online travel community . The website is home to ...
(Date:1/22/2015)... Glendale, AZ (PRWEB) January 22, 2015 Padre ... a long supporter of Pro Player Health Alliance ... with Padre Murphy's in getting everyone, including NFL greats, treated ... one of the leading groups supporting the cause in the ...
(Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... University of Rochester has been awarded a U.S. patent for ... The patent is for the creation of virus-like particles ... the majority of all cancers related to HPV including about ... and also cancers that affect the vulva, vagina, penis, and ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... Alzheimer,s disease are more likely to be underweight than people ... suggests. "Weight loss may be a manifestation of ... a study appearing in the Nov. 22 issue of ...
... idea is that we,re using the most appropriate technology ... on one technique," explains EAE President Dr Luigi Badano, ... echocardiography, he adds, magnetic resonance imaging, computed tomography and ... offering delegates a unique opportunity for an in-depth education ...
... HEP i-chart, that provides Hepatitis C (HCV) patients with quick ... Hepatitis C was first discovered in the 1980s ... (not the already known hepatitis A or B) causing liver ... liver. It is estimated that over 170million individuals ...
... HealthDay Reporter , MONDAY, Nov. 21 (HealthDay News) -- Thin people ... of an operation than heavier people, researchers have found. ... said. They set out to see what effect obesity had on ... was, the greater the risk of death. The measurement the ...
... in French . Although police officers are ... their work, they are no more likely than the general ... the findings from the second phase of an original and ... sant et en scurit du travail (IRSST) on the risk ...
Cached Medicine News:Health News:US patent awarded for Rochester's pioneering HPV vaccine work 2Health News:Could Weight Loss Be Early Sign of Alzheimer's? 2Health News:New and varied imaging techniques facilitate personalized medicine 2Health News:University launches iphone app for hepatitis treatment 2Health News:Thin People May Be at Greater Risk for Post-Surgery Death 2Health News:Thin People May Be at Greater Risk for Post-Surgery Death 3Health News:Post-traumatic stress risk to police officers lower than previously thought 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: